Rights to Crohn's disease candidate returned to ChemoCentryx

09/19/2013 | Genetic Engineering & Biotechnology News

ChemoCentryx has regained all rights to the experimental drug vercirnon from GlaxoSmithKline following a late-stage trial. The drug failed to meet its main goal and an important secondary goal in the SHIELD-1 study of patients with moderately to severely active Crohn's disease. The move "confers to us many degrees of freedom in deciding this valuable asset's forward path," ChemoCentryx President and CEO Thomas J. Schall said.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA